150 related articles for article (PubMed ID: 12535740)
1. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin.
Eid HM; Eritsland J; Larsen J; Arnesen H; Seljeflot I
Atherosclerosis; 2003 Feb; 166(2):279-84. PubMed ID: 12535740
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
Böger RH; Bode-Böger SM; Szuba A; Tsao PS; Chan JR; Tangphao O; Blaschke TF; Cooke JP
Circulation; 1998 Nov; 98(18):1842-7. PubMed ID: 9799202
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
[TBL] [Abstract][Full Text] [Related]
4. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins.
Santilli F; Bucciarelli L; Noto D; Cefalù AB; Davì V; Ferrante E; Pettinella C; Averna MR; Ciabattoni G; Davì G
Free Radic Biol Med; 2007 Nov; 43(9):1255-62. PubMed ID: 17893038
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.
Raskin P; Ganda OP; Schwartz S; Willard D; Rosenstock J; Lodewick PA; Cressman MD; Phillipson B; Weiner B; McGovern ME
Am J Med; 1995 Oct; 99(4):362-9. PubMed ID: 7573090
[TBL] [Abstract][Full Text] [Related]
6. Asymmetric dimethylarginine--mechanisms and targets for therapeutic management.
Vladimirova-Kitova LG
Folia Med (Plovdiv); 2008; 50(1):12-21. PubMed ID: 18543783
[TBL] [Abstract][Full Text] [Related]
7. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.
Lu TM; Ding YA; Leu HB; Yin WH; Sheu WH; Chu KM
Am J Cardiol; 2004 Jul; 94(2):157-61. PubMed ID: 15246890
[TBL] [Abstract][Full Text] [Related]
8. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations.
Altinova AE; Arslan M; Sepici-Dincel A; Akturk M; Altan N; Toruner FB
J Clin Endocrinol Metab; 2007 May; 92(5):1881-5. PubMed ID: 17311854
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Lewis JH; Mortensen ME; Zweig S; Fusco MJ; Medoff JR; Belder R;
Hepatology; 2007 Nov; 46(5):1453-63. PubMed ID: 17668878
[TBL] [Abstract][Full Text] [Related]
10. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans.
Chan JR; Böger RH; Bode-Böger SM; Tangphao O; Tsao PS; Blaschke TF; Cooke JP
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1040-6. PubMed ID: 10764670
[TBL] [Abstract][Full Text] [Related]
11. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
Salonen R; Nyyssönen K; Porkkala E; Rummukainen J; Belder R; Park JS; Salonen JT
Circulation; 1995 Oct; 92(7):1758-64. PubMed ID: 7671358
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin and asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia.
Vladimirova-Kitova LG; Deneva TI
Clin Lab; 2010; 56(7-8):291-302. PubMed ID: 20857893
[TBL] [Abstract][Full Text] [Related]
13. The Arginine/ADMA Ratio Is Related to the Prevention of Atherosclerotic Plaques in Hypercholesterolemic Rabbits When Giving a Combined Therapy with Atorvastatine and Arginine.
Brinkmann SJ; Wörner EA; Buijs N; Richir M; Cynober L; van Leeuwen PA; Couderc R
Int J Mol Sci; 2015 May; 16(6):12230-42. PubMed ID: 26035753
[TBL] [Abstract][Full Text] [Related]
14. Pravastatin in diabetes-associated hypercholesterolemia.
Rustemeijer C; Schouten JA; Janssens EN; Spooren PF; van Doormaal JJ
Acta Diabetol; 1997 Dec; 34(4):294-300. PubMed ID: 9451475
[TBL] [Abstract][Full Text] [Related]
15. The effect of simvastatin on asymmetric dimethylarginine and flow-mediated vasodilation after optimizing the LDL level: a randomized, placebo-controlled study.
Vladimirova-Kitova LG; Deneva-Koycheva TI
Vascul Pharmacol; 2012; 56(3-4):122-30. PubMed ID: 22108444
[TBL] [Abstract][Full Text] [Related]
16. Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Nishiyama Y; Ueda M; Otsuka T; Katsura K; Abe A; Nagayama H; Katayama Y
J Atheroscler Thromb; 2011; 18(2):131-7. PubMed ID: 21081834
[TBL] [Abstract][Full Text] [Related]
17. Relationship between asymmetric dimethylarginine and asymptomatic carotid atherosclerosis.
Riccioni G; Bucciarelli V; Scotti L; Aceto A; D Orazio N; Di Ilio E; Bucciarelli T
J Biol Regul Homeost Agents; 2010; 24(3):351-8. PubMed ID: 20846483
[TBL] [Abstract][Full Text] [Related]
18. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine.
Eid HM; Arnesen H; Hjerkinn EM; Lyberg T; Seljeflot I
Metabolism; 2004 Dec; 53(12):1574-9. PubMed ID: 15562402
[TBL] [Abstract][Full Text] [Related]
19. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome.
Oguz A; Uzunlulu M
Int Heart J; 2008 May; 49(3):303-11. PubMed ID: 18612188
[TBL] [Abstract][Full Text] [Related]
20. Dietary composition as a determinant of plasma asymmetric dimethylarginine in subjects with mild hypercholesterolemia.
Päivä H; Lehtimäki T; Laakso J; Ruokonen I; Tervonen R; Metso S; Nikkilä M; Wuolijoki E; Laaksonen R
Metabolism; 2004 Aug; 53(8):1072-5. PubMed ID: 15281021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
